CUREVO
Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.
CUREVO
Social Links:
Industry:
Biopharma Biotechnology
Founded:
2018-01-01
Website Url:
http://www.curevovaccine.com
Total Employee:
1+
Status:
Active
Contact:
1(206)492-5722
Total Funding:
60 M USD
Technology used in webpage:
Domain Not Resolving Microsoft Exchange Online
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.
Current Employees Featured
Investors List
Janus Henderson Investors
Janus Henderson Investors investment in Series A - Curevo
E&Investment
E&Investment investment in Series A - Curevo
RA Capital Management
RA Capital Management investment in Series A - Curevo
Green Cross Holding Corp
Green Cross Holding Corp investment in Series A - Curevo
Adjuvant Capital
Adjuvant Capital investment in Series A - Curevo
Official Site Inspections
http://www.curevovaccine.com
- Host name: 192.0.78.194
- IP address: 192.0.78.194
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "Curevo"
About Us - Curevo Vaccine
By curevovaccine. 12 Jan, 2025. Press Releases. Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine. by curevovaccine. 08 Jan, 2025. Press Releases. Curevo Vaccine to present at the 43rd Annual …See details»
Management Team - Curevo Vaccine
Executive Team Board of Directors Scientific Advisors Executive Team Linkedin George Simeon CEO & Board Director George Simeon is the CEO of Curevo Vaccine. He joined Curevo at the beginning of 2019 and has over 30 years of …See details»
Curevo - Crunchbase Company Profile & Funding
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as …See details»
Curevo Vaccine - LinkedIn
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent …See details»
Curevo, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Curevovaccine.com. Startups | Holding Company | 2018 | Washington, United States | 10-50 | curevovaccine.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. Translational …See details»
Curevo Vaccine 2025 Company Profile: Valuation, Funding
Curevo Vaccine General Information Description. Developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response. The company leverages …See details»
Curevo Vaccine - VentureRadar
Website: http://www.curevovaccine.com/ They combine excellence in protein structural biology and adjuvant / vaccine formulation to create the next generation of ...See details»
Curevo Vaccine Company Profile | Management and Employees …
[email protected]: Curevo Vaccine Top Competitors. Company Employees Revenue Top technologies; Regenerative Medicine Now. 6: $5.5 M: PAI Life Sciences Inc. 8: $1.5 M: …See details»
Curevo Vaccine Inc. - BIO Investor Forum | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... www.curevovaccine.com. …See details»
Our History - Curevo Vaccine
Our Mission Safety. Supply. Efficacy. By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of adjuvanted subunit vaccines of global importance …See details»
Curevo Raises $110 Million to Advance Amezosvatein Shingles
Mar 17, 2025 Curevo Vaccine closes a $110 million Series B round led by Medicxi, with new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures....See details»
Founder Lodge | Curevo Vaccine raises $110,000,000 at Series B on …
19/03/2025; Series B; $110,000,000 ; Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) …See details»
Curevo Vaccine to present at the 43rd Annual J.P. Morgan
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease …See details»
Curevo Vaccine Announces $26 Million Series A1 Financing to …
Nov 16, 2022 -- Curevo’s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has completed enrollment in a 678-patient Phase 2b head-to-head trial of CRV-101 …See details»
Curevo Vaccine Announces Robust Antibody Response Results of …
Sep 15, 2020 SEATTLE--(BUSINESS WIRE)--Sep 15, 2020-- Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious …See details»
Partnerships - Curevo Vaccine
As a nonprofit global research organization, MIBR (Mogam Institute for Biomedical Research) is engaged in basic discovery research to combat infectious diseases, cancer, and rare …See details»
Fully-funded Gavi, the Vaccine Alliance, is a lifeline for child ...
2 days ago Safeguarding children and adolescents from deadly, yet preventable diseases, such as polio, measles, diphtheria, pertussis, human papillomavirus and tetanus, among others, is …See details»
5 years of COVID-19 underscore value of coordinated efforts to …
Five years ago, on March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The novel coronavirus, dubbed SARS-CoV-2, began as a …See details»
GC Pharma to Establish Curevo - Curevo Vaccine
May 18, 2018 August 15, 2022 curevovaccine News, Vaccines No Comments. GC Pharma to Establish Curevo – a Seattle-based New Company Dedicated to Development of New …See details»
Curevo Vaccine (USA) Funding: $196M - medicalstartups.org
Mar 11, 2025 Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious...See details»